A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies (clinicaltrials.gov) - Oct 21, 2026 - P1/2 | N=94 | Active, not recruiting | Sponsor: Deciphera Pharmaceuticals, LLC | Recruiting ➔ Active, not recruiting
Enrollment closed • Oncology • Sarcoma • KIT • PDGFRA
|